ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag cancer policy

Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Those We Lost in 2018
Ashley Yeager | Dec 26, 2018 | 10+ min read
The scientific community said goodbye to a number of leading researchers this year.
Opinion: How HIV Became Positive
JJ More | Sep 17, 2013 | 3 min read
Immunotherapies, such as the re-engineered T cells that last year saved a 7-year-old girl’s life, continue to show promise as cancer treatments.
It's all about Cells
Miltenyi Biotec | Jan 12, 2009 | 2 min read
It's all about cells Miltenyi Biotec products and services benefit the biomedical research community worldwide In 1989, a success story began in Bergisch Gladbach near Cologne: MACS® Technology was developed, an efficient and reliable method to tag and separate cells magnetically. Since then, the Miltenyi Biotec team has grown to more than 1,100 employees. They produce and market over 1,400 products for the biomedical research community worldwide,
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Notebook
The Scientist Staff | Apr 26, 1998 | 8 min read
WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were
Letters
The Scientist Staff | Aug 1, 2006 | 5 min read
Restoring natural capital As scientists and practitioners committed to ecological restoration, we found the analogy you made in your April issue1 between restoring natural capital (RNC)2 and new forms of cancer treatment3 to be an extremely powerful one. To a certain degree, RNC and ecological restoration in general, are indeed related to ecosystem degradation in the way that tumor ecology-based treatments are related to traditional cancer therapies, e.g., combined

Run a Search

ADVERTISEMENT